New combo therapy aims to boost colon cancer treatment before surgery
NCT ID NCT07468630
First seen Mar 16, 2026 · Last updated Jun 17, 2026 · Updated 12 times
Summary
This study tests whether adding tolecizumab (a PCSK9 inhibitor) to standard chemoimmunotherapy can better shrink locally advanced colon cancer before surgery. About 106 adults with a specific type of colon cancer will receive either the combination or standard treatment alone. The main goal is to see if the cancer disappears completely in the surgical sample.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Daping Hospital Third Military Medical University, chongqing, chongqing 400000 Recruiting
RECRUITINGChongqing, Chongqing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.